Research compendium

Efpeglenatide

Efpeglenatide combines an exendin peptide analog, a PEG linker and an immunoglobulin Fc fragment. Calling it a free peptide omits essential identity. Its literature combines clinical-event evaluation with pharmacokinetic exposure modeling.

This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.

What is established and what remains a hypothesis

Keep source limits and editorial status visible. A proposed mechanism should not be presented as a confirmed property in every context.

Is the source the original work, a review or a later interpretation?
Has the observation been reproduced under independent conditions?
Does the material defined in the paper match the entity named in this entry?

Find readings for this question

Mechanism described in the literature

Efpeglenatide is classified as a GLP-1 receptor agonist. The conjugated architecture belongs to the studied entity; results do not transfer to free exendin or any other Fc-containing construct.

Classification

Peptide conjugate with PEG and an Fc fragment

Other names

Efpeglenatide
HM11260C

Clinical events in a defined population

In AMPLITUDE-O adults with type 2 diabetes and elevated cardiovascular or renal risk, efpeglenatide showed fewer composite cardiovascular endpoint events than placebo. That selected population limits extrapolation to people without diabetes. A composite result also does not separately establish a difference in every component event.

What an exposure model represents

Population pharmacokinetic analysis pooled six studies in people with obesity or type 2 diabetes, examining variability and covariates including body weight. Predictions describe exposure within the data and assumptions used; they are not an independent bioequivalence experiment.

Identity, exposure and outcome

Composition identifies the conjugate, pharmacokinetics characterizes its presence in the body, and an event trial measures a clinical consequence in specific participants. These levels do not replace each other. Exposure predictions cannot retrospectively establish benefits absent from a study’s measurements.

Questions and answers

Is it only a small peptide?

No. The conjugate includes a peptide component, PEG and an Fc fragment.

Are AMPLITUDE-O and the pharmacokinetic model interchangeable?

No. One compared clinical events; the other analyzed concentrations and exposure variability.